Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

8 Citeringar (SciVal)

Sammanfattning

To study frequency, possible baseline predictors, timing, and duration of sustained remission [SR; defined as 28-joint Disease Activity Score (DAS28) < 2.6 for at least 6 mos] in patients with established rheumatoid arthritis (RA) treated with different tumor necrosis factor (TNF) inhibitors [etanercept (ETN), infliximab (IFX), adalimumab (ADA)]. In addition, the aim was to compare (head-to-head) the effectiveness of individual drugs in patients receiving their first anti-TNF treatment.
Originalspråkengelska
Sidor (från-till)741-748
TidskriftJournal of Rheumatology
Volym42
Utgåva5
DOI
StatusPublished - 2015

Ämnesklassifikation (UKÄ)

  • Reumatologi och inflammation

Fingeravtryck

Utforska forskningsämnen för ”Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här